Progressive Pulmonary Fibrosis (PPF) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The progressive pulmonary fibrosis (PPF) market has been comprehensively analyzed in IMARC's new report titled "Progressive Pulmonary Fibrosis (PPF) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Progressive pulmonary fibrosis (PPF) is a debilitating respiratory condition characterized by the gradual and irreversible scarring of lung tissue, leading to impaired pulmonary function. This condition often manifests insidiously, with symptoms intensifying over time. Individuals suffering from PPF may experience persistent cough, shortness of breath, and fatigue, significantly impacting their daily lives. As the fibrotic tissue accumulates in the lungs, the vital exchange of oxygen and carbon dioxide becomes compromised, further exacerbating respiratory distress. Diagnosing PPF typically involves a thorough medical history review, physical examinations, and imaging studies such as high-resolution computed tomography (HRCT) scans. Pulmonary function tests are also crucial for assessing lung capacity and function. Additionally, a lung biopsy may be performed to confirm the presence of fibrosis and rule out various other potential causes of similar symptoms.
The escalating prevalence of genetic mutations, which can instigate a relentless progression of fibrous tissue in the lungs, impairing respiratory function and leading to severe health implications, is primarily driving the progressive pulmonary fibrosis (PPF) market. In addition to this, the inflating utilization of advanced pharmaceutical interventions, including antifibrotic agents, immunosuppressants, and novel therapies targeting specific molecular pathways, is also creating a positive outlook for the market. This proactive approach aims not only to alleviate symptoms but also to impede the relentless fibrotic cascade, thereby preventing further damage. Moreover, the widespread adoption of pulmonary rehabilitation programs, encompassing tailored exercise regimens and respiratory therapies to enhance lung capacity, ameliorate respiratory distress, and improve overall quality of life for individuals suffering from PPF is also bolstering the market growth. Apart from this, the rising usage of cutting-edge procedures like lung transplantation for advanced cases, which underscores a comprehensive approach in managing the debilitating condition, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene therapy, involving the precise introduction of functional genetic material to rectify or replace mutated genes leading to the fibrotic process, is expected to drive the progressive pulmonary fibrosis (PPF) market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the progressive pulmonary fibrosis (PPF) market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for progressive pulmonary fibrosis (PPF) and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the progressive pulmonary fibrosis (PPF) market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the progressive pulmonary fibrosis (PPF) market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the progressive pulmonary fibrosis (PPF) market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape
This report also provides a detailed analysis of the current progressive pulmonary fibrosis (PPF) marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report
Key Questions Answered in this Report
Market Insights
How has the progressive pulmonary fibrosis (PPF) market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the progressive pulmonary fibrosis (PPF) market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the progressive pulmonary fibrosis (PPF) market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of progressive pulmonary fibrosis (PPF) across the seven major markets?
What is the number of prevalent cases (2018-2034) of progressive pulmonary fibrosis (PPF) by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of progressive pulmonary fibrosis (PPF) by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with progressive pulmonary fibrosis (PPF) across the seven major markets?
What is the size of the progressive pulmonary fibrosis (PPF) patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of progressive pulmonary fibrosis (PPF)?
What will be the growth rate of patients across the seven major markets?
Progressive Pulmonary Fibrosis (PPF): Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for progressive pulmonary fibrosis (PPF) drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the progressive pulmonary fibrosis (PPF) market?
What are the key regulatory events related to the progressive pulmonary fibrosis (PPF) market?
What is the structure of clinical trial landscape by status related to the progressive pulmonary fibrosis (PPF) market?
What is the structure of clinical trial landscape by phase related to the progressive pulmonary fibrosis (PPF) market?
What is the structure of clinical trial landscape by route of administration related to the progressive pulmonary fibrosis (PPF) market?
The escalating prevalence of genetic mutations, which can instigate a relentless progression of fibrous tissue in the lungs, impairing respiratory function and leading to severe health implications, is primarily driving the progressive pulmonary fibrosis (PPF) market. In addition to this, the inflating utilization of advanced pharmaceutical interventions, including antifibrotic agents, immunosuppressants, and novel therapies targeting specific molecular pathways, is also creating a positive outlook for the market. This proactive approach aims not only to alleviate symptoms but also to impede the relentless fibrotic cascade, thereby preventing further damage. Moreover, the widespread adoption of pulmonary rehabilitation programs, encompassing tailored exercise regimens and respiratory therapies to enhance lung capacity, ameliorate respiratory distress, and improve overall quality of life for individuals suffering from PPF is also bolstering the market growth. Apart from this, the rising usage of cutting-edge procedures like lung transplantation for advanced cases, which underscores a comprehensive approach in managing the debilitating condition, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene therapy, involving the precise introduction of functional genetic material to rectify or replace mutated genes leading to the fibrotic process, is expected to drive the progressive pulmonary fibrosis (PPF) market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the progressive pulmonary fibrosis (PPF) market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for progressive pulmonary fibrosis (PPF) and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the progressive pulmonary fibrosis (PPF) market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the progressive pulmonary fibrosis (PPF) market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the progressive pulmonary fibrosis (PPF) market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape
This report also provides a detailed analysis of the current progressive pulmonary fibrosis (PPF) marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report
Key Questions Answered in this Report
Market Insights
How has the progressive pulmonary fibrosis (PPF) market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the progressive pulmonary fibrosis (PPF) market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the progressive pulmonary fibrosis (PPF) market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of progressive pulmonary fibrosis (PPF) across the seven major markets?
What is the number of prevalent cases (2018-2034) of progressive pulmonary fibrosis (PPF) by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of progressive pulmonary fibrosis (PPF) by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with progressive pulmonary fibrosis (PPF) across the seven major markets?
What is the size of the progressive pulmonary fibrosis (PPF) patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of progressive pulmonary fibrosis (PPF)?
What will be the growth rate of patients across the seven major markets?
Progressive Pulmonary Fibrosis (PPF): Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for progressive pulmonary fibrosis (PPF) drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the progressive pulmonary fibrosis (PPF) market?
What are the key regulatory events related to the progressive pulmonary fibrosis (PPF) market?
What is the structure of clinical trial landscape by status related to the progressive pulmonary fibrosis (PPF) market?
What is the structure of clinical trial landscape by phase related to the progressive pulmonary fibrosis (PPF) market?
What is the structure of clinical trial landscape by route of administration related to the progressive pulmonary fibrosis (PPF) market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 PROGRESSIVE PULMONARY FIBROSIS (PPF) - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 PROGRESSIVE PULMONARY FIBROSIS (PPF) - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 PROGRESSIVE PULMONARY FIBROSIS (PPF) - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 PROGRESSIVE PULMONARY FIBROSIS (PPF) - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 PROGRESSIVE PULMONARY FIBROSIS (PPF) - UNMET NEEDS
10 PROGRESSIVE PULMONARY FIBROSIS (PPF) - KEY ENDPOINTS OF TREATMENT
11 PROGRESSIVE PULMONARY FIBROSIS (PPF) - MARKETED PRODUCTS
11.1 List of Progressive Pulmonary Fibrosis (PPF) Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 PROGRESSIVE PULMONARY FIBROSIS (PPF) - PIPELINE DRUGS
12.1 List of Progressive Pulmonary Fibrosis (PPF) Pipeline Drugs Across the Top 7 Markets
12.1.1 BMS-986278 - Bristol-Myers Squibb
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 BI 1015550 - Boehringer Ingelheim
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report
13. PROGRESSIVE PULMONARY FIBROSIS (PPF) - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. PROGRESSIVE PULMONARY FIBROSIS (PPF) – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 PROGRESSIVE PULMONARY FIBROSIS (PPF) - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Progressive Pulmonary Fibrosis (PPF) - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Progressive Pulmonary Fibrosis (PPF) - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Progressive Pulmonary Fibrosis (PPF) - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Progressive Pulmonary Fibrosis (PPF) - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Progressive Pulmonary Fibrosis (PPF) - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Progressive Pulmonary Fibrosis (PPF) - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Progressive Pulmonary Fibrosis (PPF) - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Progressive Pulmonary Fibrosis (PPF) - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Progressive Pulmonary Fibrosis (PPF) - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Progressive Pulmonary Fibrosis (PPF) - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Progressive Pulmonary Fibrosis (PPF) - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Progressive Pulmonary Fibrosis (PPF) - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Progressive Pulmonary Fibrosis (PPF) - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Progressive Pulmonary Fibrosis (PPF) - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Progressive Pulmonary Fibrosis (PPF) - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Progressive Pulmonary Fibrosis (PPF) - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Progressive Pulmonary Fibrosis (PPF) - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Progressive Pulmonary Fibrosis (PPF) - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Progressive Pulmonary Fibrosis (PPF) - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Progressive Pulmonary Fibrosis (PPF) - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Progressive Pulmonary Fibrosis (PPF) - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Progressive Pulmonary Fibrosis (PPF) - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Progressive Pulmonary Fibrosis (PPF) - Access and Reimbursement Overview
16 PROGRESSIVE PULMONARY FIBROSIS (PPF) - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 PROGRESSIVE PULMONARY FIBROSIS (PPF) MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 PROGRESSIVE PULMONARY FIBROSIS (PPF) MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 PROGRESSIVE PULMONARY FIBROSIS (PPF) - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 PROGRESSIVE PULMONARY FIBROSIS (PPF) - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 PROGRESSIVE PULMONARY FIBROSIS (PPF) - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 PROGRESSIVE PULMONARY FIBROSIS (PPF) - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 PROGRESSIVE PULMONARY FIBROSIS (PPF) - UNMET NEEDS
10 PROGRESSIVE PULMONARY FIBROSIS (PPF) - KEY ENDPOINTS OF TREATMENT
11 PROGRESSIVE PULMONARY FIBROSIS (PPF) - MARKETED PRODUCTS
11.1 List of Progressive Pulmonary Fibrosis (PPF) Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 PROGRESSIVE PULMONARY FIBROSIS (PPF) - PIPELINE DRUGS
12.1 List of Progressive Pulmonary Fibrosis (PPF) Pipeline Drugs Across the Top 7 Markets
12.1.1 BMS-986278 - Bristol-Myers Squibb
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 BI 1015550 - Boehringer Ingelheim
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report
13. PROGRESSIVE PULMONARY FIBROSIS (PPF) - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. PROGRESSIVE PULMONARY FIBROSIS (PPF) – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 PROGRESSIVE PULMONARY FIBROSIS (PPF) - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Progressive Pulmonary Fibrosis (PPF) - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Progressive Pulmonary Fibrosis (PPF) - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Progressive Pulmonary Fibrosis (PPF) - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Progressive Pulmonary Fibrosis (PPF) - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Progressive Pulmonary Fibrosis (PPF) - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Progressive Pulmonary Fibrosis (PPF) - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Progressive Pulmonary Fibrosis (PPF) - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Progressive Pulmonary Fibrosis (PPF) - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Progressive Pulmonary Fibrosis (PPF) - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Progressive Pulmonary Fibrosis (PPF) - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Progressive Pulmonary Fibrosis (PPF) - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Progressive Pulmonary Fibrosis (PPF) - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Progressive Pulmonary Fibrosis (PPF) - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Progressive Pulmonary Fibrosis (PPF) - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Progressive Pulmonary Fibrosis (PPF) - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Progressive Pulmonary Fibrosis (PPF) - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Progressive Pulmonary Fibrosis (PPF) - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Progressive Pulmonary Fibrosis (PPF) - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Progressive Pulmonary Fibrosis (PPF) - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Progressive Pulmonary Fibrosis (PPF) - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Progressive Pulmonary Fibrosis (PPF) - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Progressive Pulmonary Fibrosis (PPF) - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Progressive Pulmonary Fibrosis (PPF) - Access and Reimbursement Overview
16 PROGRESSIVE PULMONARY FIBROSIS (PPF) - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 PROGRESSIVE PULMONARY FIBROSIS (PPF) MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 PROGRESSIVE PULMONARY FIBROSIS (PPF) MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
